Stocks and Investing Stocks and Investing
Mon, May 6, 2024

Andrew Berens Upgraded (BPMC) to Hold and Increased Target to $97 on, May 6th, 2024


Published on 2024-10-28 11:00:52 - WOPRAI, Andrew Berens
  Print publication without navigation


Andrew Berens of Leerink Partners, Upgraded "Blueprint Medicines Corporation" (BPMC) to Hold and Increased Target from $50 to $97 on, May 6th, 2024.

Andrew has made no other calls on BPMC in the last 4 months.



There are 8 other peers that have a rating on BPMC. Out of the 8 peers that are also analyzing BPMC, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Increased Target to $104 on, Friday, May 3rd, 2024
  • Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $75 on, Friday, May 3rd, 2024


These are the ratings of the 6 analyists that currently disagree with Andrew


  • Ami Fadia of "Needham" Maintained at Strong Buy with Increased Target to $130 on, Friday, May 3rd, 2024
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $135 on, Friday, May 3rd, 2024
  • David Lebowitz of "Citigroup" Maintained at Strong Sell with Increased Target to $76 on, Friday, May 3rd, 2024
  • Reni Benjamin of "JMP Securities" Maintained at Buy with Increased Target to $125 on, Friday, May 3rd, 2024
  • David Nierengarten of "Wedbush" Reiterated at Buy and Held Target at $110 on, Friday, April 26th, 2024
  • Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $130 on, Friday, April 26th, 2024
Contributing Sources